Catalent Completes Accucaps Acquisition

Article

PTSM: Pharmaceutical Technology Sourcing and Management

PTSM: Pharmaceutical Technology Sourcing and ManagementPTSM: Pharmaceutical Technology Sourcing and Management-03-01-2017
Volume 12
Issue 3

The acquisition complements Catalent’s global OTC and prescription pharmaceutical softgel capabilities and capacity.

CDMO Catalent announced that it has completed the acquisition of Accucaps, the Canada-based developer and manufacturer of over-the-counter (OTC), high-potency and conventional pharmaceutical softgels. No financial details of the transaction were disclosed.

The acquisition complements Catalent’s global OTC and prescription pharmaceutical softgel capabilities and capacity, adding a portfolio of products supplied to pharmaceutical companies in North America, and two state-of-the-art facilities offering integrated softgel development, manufacturing, and packaging. Accucaps’ facilities house sizeable blistering, bottling, and other packaging capabilities, as well as high-potency prescription softgel development and manufacturing expertise that are complementary to Catalent’s. More than 500 employees at Accucaps at the facilities in Windsor and Strathroy, Ontario, have joined Catalent’s network of 11 softgel technologies facilities.

Source: Catalent

Recent Videos
Behind the Headlines, episode 7
Behind the Headlines episode 6
CPHI Milan 2024: Highlighting the Benefits of Integrated Services
Behind the Headlines episode 5
Buy, Sell, Hold: Cell and Gene Therapy
Buy, Sell, Hold: Cell and Gene Therapy
Related Content